• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

隐球菌性肺炎:一名新冠肺炎患者的罕见并发症

Cryptococcal Pneumonia: An Unusual Complication in a COVID-19 Patient.

作者信息

Štingl Jan, Hylmarová Julie, Lengerová Martina, Maláska Jan, Stašek Jan

机构信息

Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.

Department of Pathological Anatomy, University Hospital Brno, 625 00 Brno, Czech Republic.

出版信息

Diagnostics (Basel). 2022 Aug 12;12(8):1944. doi: 10.3390/diagnostics12081944.

DOI:10.3390/diagnostics12081944
PMID:36010294
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9406651/
Abstract

Cryptococcal superinfection is a rare but potentially fatal complication, especially if its detection and subsequent treatment are delayed. Histopathological findings of pulmonary parenchyma from a deceased patient with these complications were acquired. Quite interestingly, only a minimal inflammatory reaction could be seen in an individual with no previously known immune suppression, indicating a disturbance of the immune system. This finding was well in concordance with the described changes in cellular immunity in COVID-19. We report the case of a 60 year old male with critical coronavirus disease 2019 (COVID-19) complicated by cryptococcal pneumonia and multiorgan failure. Both X-ray and CT scans revealed lung infiltrates corresponding with COVID-19 infection early after the onset of symptoms. Despite receiving standard treatment, the patient progressed into multiple organ failure, requiring mechanical ventilation, circulatory support, and haemodialysis. was detected by subsequent BAL, and specific antifungal treatment was instituted. His clinical status deteriorated despite all treatment, and he died of refractory circulatory failure after 21 days from hospital admission. Histopathological findings confirmed severe diffuse alveolar damage (DAD) caused by COVID-19 and cryptococcal pneumonia. Timely diagnosis of cryptococcal superinfection may be challenging; therefore, PCR panels detecting even uncommon pathogens should be implemented while taking care of critical COVID-19 patients.

摘要

隐球菌二重感染是一种罕见但可能致命的并发症,尤其是在其检测及后续治疗延迟的情况下。获取了一名患有这些并发症的已故患者肺实质的组织病理学检查结果。非常有趣的是,在一名既往无已知免疫抑制的个体中仅可见轻微的炎症反应,这表明免疫系统受到了干扰。这一发现与新冠病毒病(COVID-19)中所描述的细胞免疫变化高度一致。我们报告了一例60岁男性重症2019冠状病毒病(COVID-19)合并隐球菌肺炎及多器官功能衰竭的病例。症状出现后早期,X线和CT扫描均显示与COVID-19感染相符的肺部浸润影。尽管接受了标准治疗,患者仍进展为多器官功能衰竭,需要机械通气、循环支持和血液透析。随后通过支气管肺泡灌洗(BAL)检测到了隐球菌,遂开始进行特异性抗真菌治疗。尽管进行了所有治疗,患者的临床状况仍恶化,入院21天后死于难治性循环衰竭。组织病理学检查结果证实了由COVID-19和隐球菌肺炎导致的严重弥漫性肺泡损伤(DAD)。隐球菌二重感染的及时诊断可能具有挑战性;因此,在救治重症COVID-19患者时应采用能检测甚至罕见病原体的聚合酶链反应(PCR)检测板。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b031/9406651/7f87a5cd8585/diagnostics-12-01944-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b031/9406651/7b917242ba5c/diagnostics-12-01944-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b031/9406651/a66b22565ca9/diagnostics-12-01944-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b031/9406651/7f87a5cd8585/diagnostics-12-01944-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b031/9406651/7b917242ba5c/diagnostics-12-01944-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b031/9406651/a66b22565ca9/diagnostics-12-01944-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b031/9406651/7f87a5cd8585/diagnostics-12-01944-g005.jpg

相似文献

1
Cryptococcal Pneumonia: An Unusual Complication in a COVID-19 Patient.隐球菌性肺炎:一名新冠肺炎患者的罕见并发症
Diagnostics (Basel). 2022 Aug 12;12(8):1944. doi: 10.3390/diagnostics12081944.
2
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
3
Cryptococcal Pneumonia in an Immunocompetent Patient: A Rare Occurrence.免疫功能正常患者的隐球菌性肺炎:一种罕见情况。
Cureus. 2022 Oct 2;14(10):e29841. doi: 10.7759/cureus.29841. eCollection 2022 Oct.
4
CD4 T Cells Orchestrate Lethal Immune Pathology despite Fungal Clearance during Meningoencephalitis.CD4 T 细胞在脑膜脑炎中尽管清除了真菌,但仍能协调致命的免疫病理。
mBio. 2017 Nov 21;8(6):e01415-17. doi: 10.1128/mBio.01415-17.
5
SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.SARS-CoV-2 感染免疫功能低下患者:体液免疫与细胞免疫。
J Immunother Cancer. 2020 Jul;8(2). doi: 10.1136/jitc-2020-000862.
6
Evolution of severe acute respiratory syndrome coronavirus 2 RNA test results in a patient with fatal coronavirus disease 2019: a case report.新型严重急性呼吸综合征冠状病毒 2 型 RNA 检测结果的演变:1 例致死性 2019 冠状病毒病患者病例报告。
Hum Pathol. 2020 Jul;101:82-88. doi: 10.1016/j.humpath.2020.04.015. Epub 2020 May 11.
7
COVID-19 pneumonia complicated by bilateral pneumothorax: A case report.新型冠状病毒肺炎合并双侧气胸:一例病例报告。
Respir Med Case Rep. 2020;31:101230. doi: 10.1016/j.rmcr.2020.101230. Epub 2020 Sep 24.
8
Diffuse alveolar damage (DAD) resulting from coronavirus disease 2019 Infection is Morphologically Indistinguishable from Other Causes of DAD.新型冠状病毒疾病 2019 感染导致的弥漫性肺泡损伤(DAD)在形态上与其他 DAD 病因无法区分。
Histopathology. 2020 Oct;77(4):570-578. doi: 10.1111/his.14180. Epub 2020 Sep 12.
9
Case report: a special case of cryptococcal infection-related inflammatory syndrome in a non-HIV infected and non-transplant patient.病例报告:一例非 HIV 感染和非移植患者与隐球菌感染相关炎症综合征的特殊病例。
BMC Neurol. 2022 Jul 6;22(1):247. doi: 10.1186/s12883-022-02773-4.
10
Rifampicin-Induced Pneumonitis Mimicking Severe COVID-19 Pneumonia Infection.利福平诱发的肺炎酷似重症新冠病毒肺炎感染
Am J Case Rep. 2020 Aug 25;21:e927586. doi: 10.12659/AJCR.927586.

引用本文的文献

1
Evolving Impact of COVID-19 on Intestinal Transplant Recipients: A Single-Center Experience.新型冠状病毒肺炎对肠道移植受者的不断演变的影响:单中心经验
Clin Transplant. 2025 Jan;39(1):e70065. doi: 10.1111/ctr.70065.
2
COVID-19 associated with cryptococcosis: a scoping review.新型冠状病毒肺炎合并隐球菌病:一项范围综述
Ther Adv Infect Dis. 2024 Feb 14;11:20499361241232851. doi: 10.1177/20499361241232851. eCollection 2024 Jan-Dec.
3
COVID-19 Associated with Cryptococcosis: A New Challenge during the Pandemic.新型冠状病毒肺炎合并隐球菌病:大流行期间的新挑战

本文引用的文献

1
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.托珠单抗治疗 COVID-19 住院患者的疗效(RECOVERY):一项随机、对照、开放标签、平台试验。
Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0.
2
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.COVID-19 重症患者的白细胞介素 6 受体拮抗剂。
N Engl J Med. 2021 Apr 22;384(16):1491-1502. doi: 10.1056/NEJMoa2100433. Epub 2021 Feb 25.
3
Cytokine Storm.细胞因子风暴
J Fungi (Basel). 2022 Oct 21;8(10):1111. doi: 10.3390/jof8101111.
N Engl J Med. 2020 Dec 3;383(23):2255-2273. doi: 10.1056/NEJMra2026131.
4
Immune suppression in the early stage of COVID-19 disease.COVID-19 疾病早期的免疫抑制。
Nat Commun. 2020 Nov 17;11(1):5859. doi: 10.1038/s41467-020-19706-9.
5
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
6
Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19).新型冠状病毒病(COVID-19)患者 T 细胞减少和功能耗竭。
Front Immunol. 2020 May 1;11:827. doi: 10.3389/fimmu.2020.00827. eCollection 2020.
7
New Approaches for Cryptococcosis Treatment.隐球菌病治疗的新方法。
Microorganisms. 2020 Apr 23;8(4):613. doi: 10.3390/microorganisms8040613.
8
Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial.地塞米松治疗急性呼吸窘迫综合征:一项多中心、随机对照试验。
Lancet Respir Med. 2020 Mar;8(3):267-276. doi: 10.1016/S2213-2600(19)30417-5. Epub 2020 Feb 7.
9
Cryptococcal infections in non-HIV-infected patients.非HIV感染患者的隐球菌感染
Trans Am Clin Climatol Assoc. 2013;124:61-79.
10
Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.《隐球菌病治疗指南:美国传染病学会 2010 年更新版》
Clin Infect Dis. 2010 Feb 1;50(3):291-322. doi: 10.1086/649858.